DTO/SD/26 (00 04)

B D BUA	2005 U	t Reduction Act of 1995 n	o persons are required to res	U.S. Patent and Tradema	red for use through 07/31/2006. OMB 0651-0031 ark Office; U.S. DEPARTMENT OF COMMERCE on unless it displays a valid OMB control number.
	#/TERMINAL	DISCLAIMER TO	OBVIATE A DOUB	LE PATENTING	Docket Number (Optional) GTC-6D
& TEAD	In re Application of: Me	eade et al.			
	Application No.: 10/081,400				
	Filed: February 20, 2002				
	For: ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION				
	The owner*, GTC Biotherapeutics. Inc, of, of, of, of				
	In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant appli would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. 1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on inform belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such vistatements may jeopardize the validity of the application or any patent issued thereon.				
	2. The undersigned is an attorney or agent of record. Reg. No. 42,960				, ,
08/11/2005	MWDLDGE1 00000041 5	502092 10081400	Bon	Dh	8/9/03
01 FC:2814			Signati		Date
				Byron V. Olsen Typed or printed name	
					(508) 370-5150 Telephone Number
	✓ Terminal dis	claimer fee under 37 Cf	R 1.20(d) included.		
				me public. Credit card infonformation and authorizati	
			f terminal disclaimer is signer title of the second	gned by the assignee (owners 324.	r).

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.